Influenza A Virus Infection
13
0
0
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
23%
3 trials in Phase 3/4
17%
2 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (13)
Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit
A Pilot Study for Collection of Anti-Influenza A Immune Plasma
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
Blood and Plasma Collection For Use in Future Clinical Trials
Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
Antiviral Therapy for Influenza A H1N1